Skip to content
Search

Latest Stories

NPA roundtable recommends action plan for pharmacists to help people with obesity

A roundtable organized by National Pharmacists Association (NPA) discussed how an enhanced role of community pharmacies could help people with obesity.

Seven action points were recommended by the delegates at the virtual event which took place on March 31, in collaboration with Novo Nordisk.


It was chaired by Professor Maggie Rae, president of the Faculty of Public Health and featured representatives from the Royal Pharmaceutical Society, Royal Society for Public Health, Patients Association, UK Health Security Agency, Diabetes UK and NHS England.

The roundtable also heard testimony from a parent of a young adult living with obesity and a presentation of the personal experience of someone living with the condition by Sarah Le Brocq, director of campaign group, All About Obesity.

The delegates came up with seven recommendations on how the role of community pharmacies can be enhanced and enabled further to help those living with obesity. They are:

  1. All people living with type 1 and type 2 diabetes should have access to weight management services with a specific focus on community pharmacy provision.
  2. Weight management and obesity services should have a greater focus on children and young adults, so that we can have the right conversations regarding healthy weight and intervene at an early point.
  3. All of us within the health and social care system should talk about people that are living with obesity. We should use this terminology to help stop the blame and stigma. It is as much an illness as any other illness.
  4. Promote community pharmacy as the setting for person centred services that can help people living with obesity. Continue to build on the strengths of community pharmacy which is a part of the NHS service offering.
  5. Use Health Champions, Social Prescribing services, and localized health services to enhance the community pharmacy service across the United Kingdom.
  6. Improving pharmacy teams’ knowledge, skills, understanding and practical application of obesity and obesity services, including the pharmacy undergraduate curriculum.
  7. Seek opportunities that are likely to emerge from the genetic and digital revolutions to improve services to those living with obesity.

Helga Mangion, policy manager at the NPA, said: “I thank those living with obesity on sharing their experiences. It was great to see so many healthcare professionals bringing together their expertise in one place and I’m delighted that the NPA was able to facilitate such an important conversation.

“With obesity levels on the increase across the UK and the ability for patients to easily access community pharmacy, community pharmacy has an important role to play in the prevention and management of the condition."

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less